Register

You do not have an Account? Register now

Headquarters / Germany
Austria
de
Belgium
fr de nl
France
fr
Italy
it
Netherlands
nl
Poland
pl
Switzerland
de fr it
United Kingdom
en
Россия (Russia)
ru
中華人民共和國 (China)
cn
India
en
USA
en
Erbe Headquarters
Erbe Worldwide

Please choose a website and your preferred language.

Skip navigation

Transbronchial lung cryobiopsy

for diagnosis of interstitial lung diseases (ILD)

In a comparative, multicenter, prospective COLDICE study, the diagnostic yield of SLB (surgical lung biopsy) was compared to that of TBLC (transbronchial lung cryobiopsy) in 65 patients. The biopsies were obtained sequentially from the same patient under anesthesia with the following result:
When the diagnosis was based on histopathological results alone, there was a 70.8% agreement between the two methods. However, when a multidisciplinary diagnosis was made, agreement increased to 76.9%. Particularly in cases of a definitive diagnosis or one that could be made with a high degree of certainty, the methods were comparable and agreed in 95% of cases.

SLB, the  gold standard to date, is associated with significant morbidity. Complications include: postoperative pneumothorax, pneumonia and respiratory failure, and a significant mortality rate of 1.7% as compared to 0.2% for TBLC.

In light of these study results, minimally invasive TBLC, when performed by experienced bronchoscopists, is recommended as the first option for patients with ILD requiring a lung biopsy. Whenever possible, surgical lung biopsy should be limited  to patients for whom cryobiopsy is not a viable diagnostic option.
These recommendations were published in the latest CHEST Guideline and Expert Panel Report (2019).


More information on the study can be found at Medical Insight.
Further applications in pulmonology can be found at Medical Videos.